RSV in Adults
How Effective Is the RSV Vaccine? A Look at Real-World Data
A large group of investigators recently examined how well vaccination against respiratory syncytial virus has done in terms of patients who experienced RSV-like symptoms and were either hospitalized or visited the emergency department.
RSV Vaccination During Pregnancy: Who’s Ready?
A study conducted at a university maternity hospital in Ireland surveyed pregnant women with regard to their awareness of the respiratory syncytial virus vaccine and how willing they were to accept it.
RSV May Increase Hospitalization Risk Among Long-term Care Facility Residents
An analysis compared estimates of RSV-associated hospitalization in community-dwelling, assisted living, and skilled nursing facility in adults aged 65 years and older.
Respiratory Syncytial Virus (RSV) in Germany: Were We Missing Something?
Population-based data revealed a sharp increase in RSV diagnoses, which the researchers attributed to increased testing during the COVID-19 pandemic.
RSV Vaccinations During Pregnancy: Improving Infant Outcomes
Does vaccination for respiratory syncytial virus (RSV) during pregnancy reduce the number of infants hospitalized with RSV infection? That was the question at the core of this literature review.
A Comparison of RSV, COVID-19, and Influenza Severity in Hospitalized US Adults
This recent study compared disease severity of adults hospitalized with RSV with those unvaccinated and vaccinated for COVID-19 and influenza, with the goal of providing clinicians with guidance for the recommendation of the RSV vaccine.
RSV Infection in Hospitalized Older Adults—and Its Dangerous Sidekick
In a new study published in JAMA Internal Medicine, patients ages 50 and older hospitalized with respiratory syncytial virus (RSV) infection who experienced an acute cardiac event in the hospital had twice the risk of dying as those who did not.
Respiratory Viruses in the ICU Aren’t All Cut from the Same Cloth
Researchers in France examined 90-day survival and burden of 4 community-acquired respiratory viruses—respiratory syncytial virus, COVID-19, seasonal influenza, and H1N1 influenza—among patients presenting to the intensive care unit.
RSV Before and During COVID: How Did Pregnant Women Do?
A study examined the prevalence and outcomes of respiratory syncytial virus (RSV) infection among pregnant and nonpregnant women in the U.S. before and during the pandemic. Here’s what the research team discovered.
COVID-19, the Flu, and Beyond: Don’t Overlook Other Respiratory Viruses
A Dutch study reveals that 30-day mortality rates for hospitalized patients with RSV, rhinovirus, or hMPV are comparable to those with influenza. While SARS-CoV-2 mortality remained higher throughout the study period, the gap narrowed over time, highlighting the need for increased research on a broader range of respiratory viruses.
RSV Plus Influenza: A Deadly Combo in Older Adults
Influenza and RSV coinfection is associated with significant mortality, with increasing age, increasing comorbidity burden, and frailty each negatively impacting patient outcomes, according to this study.
RSV in France: A Hidden Burden in Adults
This study revealed a 10-fold increase in respiratory syncytial virus (RSV) hospitalizations among French adults from 2012 to 2021, highlighting the impact of RSV in this population.
.jpg)
RSV Hospitalization: Are Patients with IBD at Greater Risk?
Using data from US healthcare organizations, investigators examined whether patients with inflammatory bowel disease suffer worse outcomes from RSV than patients without IBD.
Fall 2023 Data on Flu, Updated COVID-19, and RSV Vaccine Coverage in US Adults
While data showed overall vaccine coverage to be lower than ideal, many surveyed reported that they would probably be vaccinated or were unsure, opening a path for increased vaccinations through provider recommendations and vaccine availability.
Severe RSV Infection Risk in Adults May Be Heightened by Comorbidities
A recent retrospective study analyzed rates of hospitalization for RSV-related causes and found that adults with comorbidities had higher rates of hospitalization compared with those without.
RSV Infection: Protecting the Most Vulnerable
RSV infection is an increasingly recognized cause of morbidity and mortality in older adults, making it crucial to identify individuals who would most benefit from the new RSV vaccines.
Respiratory Syncytial Virus: Are Platelets Partly to Blame?
Despite binding to respiratory syncytial virus particles, platelets do not undergo activation or degranulation, suggesting they do not contribute directly to the immune response causing severe RSV infections.
RSV Causes More Hospitalizations, Deaths Than Influenza in Older Adults
RSV is a common cause of respiratory tract infections in older adults that cannot be clinically distinguished from influenza or SARS-CoV-2 infections. It also causes more morbidity and mortality than influenza in this group of patients.
Details on the Burden of Respiratory Syncytial Virus Disease
Lower respiratory tract infections caused by human respiratory syncytial virus are the leading cause of death by communicable diseases in the world. This study on hospitalized Canadian adults add to the data by examining the disease burden, incidence, and healthcare costs of RSV.
The Challenge of Establishing Severe Acute Respiratory Surveillance
Research from Ireland reported the requirements for setting up SARI surveillance successfully, including barriers encountered that may challenge efforts, to guide others in setting up similar programs.
Not the News We Want to Hear: Antibiotics for Adults with Viral Respiratory Infections
A study conducted with data from a single hospital in Norway suggests that healthcare systems may need to reevaluate how antibiotics are delivered to patients who present at the hospital with symptoms of a viral respiratory tract infection.
Against Respiratory Syncytial Virus: Some New Projections
Research is shedding light on the true burden of respiratory syncytial virus (RSV) on the U.S. population, especially more-vulnerable older adults. So, what sort of difference will new vaccines against RSV make?
In Hospitalized Adults With RSV, What Drives Intensive Care and Mortality?
French investigators took on the task of characterizing hospitalization in adult RSV patients, identifying factors associated with admission to the intensive care unit and mortality.
RSV in Adults: Assessing Its True Burden
A new study takes an in-depth look at the disease burden of confirmed respiratory syncytial virus-acute respiratory infections (cRSV-ARIs) in community-dwelling adults compared with that of patients in long-term care facilities.
The RSV Burden is Climbing Among Older Adults in Affluent Countries
These findings suggest that the number of respiratory syncytial virus–acute respiratory infection cases, hospitalizations, and in-hospital deaths in at-risk populations could reach 5.7 million by 2025.
Respiratory Syncytial Virus in Adults: An Update on Its Diagnosis and Impact
A recent analysis indicates that cough is the most common presentation of respiratory syncytial virus (RSV) in high-risk populations and, depending on which country or region of the world patients live in, symptoms may last for weeks.
RSV in Older Adults Before and After COVID: A Primary Care Analysis
A large community-based cohort study underscores the burden of infection in older populations and the potential need for, and benefits of, public health measures to curb respiratory syncytial virus (RSV).